Ovid Therapeutics - Announcement

AP Com News OVID
  • Published: 2 Dec 2020

Ovid Therapeutics - a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases - yesterday announced the topline results from the Company’s Phase III NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.

The primary endpoint of the NEPTUNE study was not achieved. 

Read Ovid press release.